As advised via PHARMAC proposal of 16 October 2018 and the notification of PHARMAC decision of 20 December 2018 there is to be a change in the listing and future sole supply of Efavirenz with emtricitabine and tenofovir disoproxil fumarate tab 600mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.

New listing from 1 April 2019

Tenofovir Disoproxil Emtricitabine Efavirenz Mylan Tab 30                                   Pharmacode 2558505                               Schedule price $106.88

Incumbent listing

Atripla Tab                                                                                                          Pharmacode 2427095                                  Schedule price $237.52

Reference pricing will apply from 1 June 2019.

HSS (Hospital Supply Status) commences 1 June 2019.

CSS (Community Supply Status) commences 1 September 2019.

Brand switch fee to apply from 1 June 2019 to 30 August 2019.

As of the date of this notification ProPharma / PWR cannot accept Atripla Tab for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted. But be very wary of holding stock.

Benefit of staying with incumbent until 30 May 2019:-

Atripla Tab : – Average dispensing is 30 tablets. Therefore 1 x 30 Atripla Tab @ $237.52 x 4% = $9.501 plus 1 x $0.253 (pack fee) giving you $9.7540

Compared to $106.88 x 3% = $3.2064 plus 1 x $0.253 (pack fee) giving you $3.4594

You MUST manage your stock so that you have ZERO stock at time of reference pricing being 1 June 2019. Failure to do so could prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author